Premium
Salvage therapy for refractory hemophagocytic lymphohistiocytosis: A review of the published experience
Author(s) -
Marsh Rebecca A.,
Jordan Michael B.,
Talano JulieAn,
Nichols Kim E.,
Kumar Ashish,
Naqvi Ahmed,
Vaiselbuh Sarah R.
Publication year - 2017
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.26308
Subject(s) - hemophagocytic lymphohistiocytosis , medicine , salvage therapy , refractory (planetary science) , intensive care medicine , pediatrics , surgery , pathology , chemotherapy , disease , astrobiology , physics
Abstract Hemophagocytic lymphohistioytosis (HLH) is a severe, life‐threatening hyperinflammatory disorder that requires prompt diagnosis and treatment. Approximately, 25–50% of patients with HLH fail to achieve remission with established regimens that include dexamethasone and etoposide, or methylprednisolone and antithymocyte globulin (ATG). Some of these patients may require salvage or alternative therapeutic approaches. There is a paucity of literature regarding effective salvage therapies for patients with refractory HLH. In this review, we summarize the published experience of four therapeutics reported for using at least two patients with HLH refractory to dexamethasone and etoposide or methylprednisolone and ATG.